# US 2026/0083748 A1 · Pharmaceutical composition containing meloxicam, a preparation method, and an application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083748 A1
- Document ID: US20260083748A1
- Status: Published application
- Kind: A1
- Application number: 19/336,937
- Filed: 2025-09-23
- Published: 2026-03-26
- Earliest claimed: 2024-09-24
- Assignees: Beijing Tide Pharmaceutical Co., Ltd.
- Applicants: Beijing Tide Pharmaceutical Co., Ltd.
- Inventors: Wanjun LIU; Jingjing ZHANG; Zhibing ZHANG; Zaiying WANG; Di LU; Zhiyang YUE; Leling GAN
- Web page: https://patentgrep.com/patent/US20260083748A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61J 1/1412: {Containers with closing means, e.g. caps}
- A61J 1/1468: {Containers characterised by specific material properties}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition containing meloxicam, a preparation method thereof, and an application thereof. The pharmaceutical composition includes meloxicam, a composite solvent, and an acidic pH regulator. The composite solvent includes a polymer compound, an alkaline compound, and an aqueous solution. The polymer compound is selected from cyclodextrin or synthetic cyclodextrin and derivatives thereof. The meloxicam composition of the present invention does not contain any organic solvent, which can effectively avoid generation of adverse reactions of pharmaceutical formulations, make drug use safer, and at the same time also reduce the environmental pollution during the preparation process of the drug.

## Claims

### Claim 1

A pharmaceutical composition containing meloxicam, wherein the pharmaceutical composition comprises meloxicam, a composite solvent, and an acidic pH regulator, wherein the composite solvent comprises a polymer compound, an alkaline compound, and an aqueous solution, and the polymer compound is selected from cyclodextrin or synthetic cyclodextrin and derivatives thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the alkaline compound is selected from sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, arginine, lysine, histidine, glycine, triethylamine, diethanolamine, or a combination of two or more thereof, preferably sodium hydroxide, sodium carbonate, or sodium bicarbonate, more preferably sodium hydroxide.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein, based on the volume of the composite solvent, the concentration of the alkaline compound is 0.01%-1% (w/v, g/mL), preferably 0.05%-0.5% (w/v, g/mL), more preferably 0.1%-0.2% (w/v, g/mL).

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the polymer compound is selected from α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin sodium, or a combination of two or more thereof, preferably sulfobutyl-β-cyclodextrin sodium.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein based on the volume of the composite solvent, the concentration of the polymer compound is 5%-40% (w/v, g/mL), preferably 8%-20% (w/v, g/mL), more preferably 10%-15% (w/v, g/mL).

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the acidic pH regulator is an acidic aqueous solution, and the pH regulator is selected from hydrochloric acid, phosphoric acid, acetic acid, lactic acid, malic acid, fumaric acid, tartaric acid, succinic acid, citric acid, or a combination of two or more thereof, preferably citric acid.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein based on the volume of the composite solvent, the concentration of the acidic pH regulator is 0.01%-1% (w/v, g/mL), preferably 0.05%-0.5% (w/v, g/mL), more preferably 0.08%-0.15% (w/v, g/mL).

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pH of the pharmaceutical composition is 6-10, preferably 7-9, more preferably 8-9.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the water in the pharmaceutical composition is selected from water for injection, distilled water, or purified water.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the drug concentration of meloxicam in the pharmaceutical composition is 1.0-15.0 mg/mL, preferably 2.0-10.0 mg/mL, more preferably 5.0-8.0 mg/mL.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further consists of:
Meloxicam 0.084 parts
Sodium hydroxide 0.020 parts
Hydroxypropyl-β-cyclodextrin 1.228 parts
Hydrochloric acid 0.015 parts
Water for injection 10 parts; or
Meloxicam 0.053 parts
Sodium hydroxide 0.014 parts
β-cyclodextrin 0.604 parts
Acetic acid 0.02 parts
Water for injection 10 parts; or
Meloxicam 0.082 parts
Sodium hydroxide 0.021 parts
Sulfobutyl-β-cyclodextrin sodium 1.232 parts
Citric acid 0.018 parts
Water for injection 9.568 parts; or
Meloxicam 0.23 parts
Sodium hydroxide 0.04 parts
Sulfobutyl-β-cyclodextrin sodium 3.982 parts
Citric acid 0.046 parts
Water for injection 10 parts; or
Meloxicam 0.076 parts
Sodium hydroxide 0.018 parts
Sulfobutyl-β-cyclodextrin sodium 1.634 parts
Lactic acid 0.018 parts
Water for injection 10 parts; or
Meloxicam 0.029 parts
Sodium hydroxide 0.014 parts
Sodium carbonate 0.018 parts
β-cyclodextrin 1.128 parts
Phosphoric acid 0.030 parts
Lactic acid Added as needed to pH 8.5
Water for injection 9.568 parts; or
Meloxicam 0.015 parts
Sodium hydroxide 0.007 parts
β-cyclodextrin 0.522 parts
Citric acid 0.007 parts
Water for injection 10 parts.

### Claim 12 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is used for parenteral administration, preferably intravenous administration.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition is in the form of an injection or lyophilized powder, with a pH value of 6-9, preferably 7-9, more preferably 8-9.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the injection is used for intravenous administration; or the composition in the form of lyophilized powder is reconstituted for intravenous administration, wherein the reconstitution solvent is selected from water for injection, physiological saline, glucose, or other reconstitution solutions suitable for injection.

### Claim 15 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the composition in the form of lyophilized powder and further includes a lyophilization stabilizer, wherein the lyophilization stabilizer includes sucrose, lactose, maltose, glucose, raffinose, fructose, or dextrin.

### Claim 16 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the composition is sterilized by high-pressure sterilization or filtration sterilization, preferably high-pressure sterilization, wherein the sterilization temperature is 100° C.-150° C., preferably 110° C.-130° C.

### Claim 17 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the aqueous liquid form of the composition is sealed under inert gas and sterilized in the final container, wherein the final container comprises ampoules or vials, preferably vials fitted with rubber stoppers and aluminum caps.

### Claim 18 (depends on 1)

A method for preparing the pharmaceutical composition according to claim 1, comprising: first adding alkaline compound and meloxicam to water, then adding polymer compound; or first adding alkaline compound and a polymer compound to water, then adding meloxicam; or adding meloxicam, an alkaline compound, and a polymer compound to water together; preferably, first adding alkaline compound and polymer compound first, then adding meloxicam.

### Claim 19 (depends on 18)

The method according to claim 18, further comprising: weighing the prescribed amounts of meloxicam, alkaline compound, and polymer compound, first adding the alkaline compound and the polymer compound to water, then adding meloxicam, stirring to dissolve to form a clear solution, adjusting the pH to 6-9 with the pH regulator, preferably 7-9, more preferably 8-9, filling into vials, and sterilizing to obtain the meloxicam solution.

### Claim 20 (depends on 19)

The method according to claim 19, wherein, the polymer compound is selected from one or more of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl-β-cyclodextrin, or sulfobutyl-β-cyclodextrin sodium, preferably sulfobutyl-β-cyclodextrin sodium.

### Claim 21 (depends on 1)

A method for treating pain by administering an effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

### Claim 22 (depends on 21)

The method according to claim 21, wherein, the pharmaceutical composition is administered for postoperative analgesia and treatment of other types of moderate to severe pain in adults.

### Claim 23 (depends on 22)

The method according to claim 22, wherein, the postoperative analgesia includes analgesia after abdominal surgery or orthopedic surgery.
